Global Anthrax Vaccines research
Global Anthrax Vaccines research

Anthrax Vaccines Comprehensive Study by Type (Live Vaccines, Cell free PA Vaccines), Application (Human Use, Animal Use), Disease Type (Cutaneous Anthrax, Gastrointestinal Anthrax, Inhalation Anthrax), End-users (Hospitals, Clinics, Vaccination Centers, Others) Players and Region - Global Market Outlook to 2025

Anthrax Vaccines Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 231 Pages 171 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Anthrax Vaccines Market?

Anthrax is a serious disease that can affect both animals and humans caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides. There are three types of anthrax including cutaneous anthrax, gastrointestinal anthrax and inhalation anthrax. The anthrax vaccine is used to protect against anthrax disease. The factors such as Increasing Incidences of Anthrax Disease and Rise in the Number of Hospitals and Clinics are driving the global anthrax vaccine market.

The market study is being classified by Type (Live Vaccines and Cell free PA Vaccines), by Application (Human Use and Animal Use) and major geographies with country level break-up.

Porton Biopharma Limited (United Kingdom), Colorado Serum Co (United States), Emergent BioSolutions Inc. (United States), Boehringer Ingelheim Animal Health (France), Merck & Co. (United States), Zoetis Inc. (United States), Bayer (Germany), Colorado Serum Co (United States), PharmAthene, Inc. (United States) and Tiankang (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Biogenesis Bago SA (Argentina) and Instituto Rosenbusch SA (Argentina).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Anthrax Vaccines market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Anthrax Vaccines market by Type, Application and Region.

On the basis of geography, the market of Anthrax Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Incidences of Anthrax Disease
  • Rise in the Number of Hospitals and Clinics

Market Trend
  • Advancements in the Medical Science
  • Robust Increase in the Distribution Channels

Restraints
  • Side Effects of the Anthrax Vaccine

Opportunities
  • Growth in the Health Care Industry Worldwide
  • Increased Healthcare Infrastructure in Developing Countries

Challenges
  • Stringent Government Rules and Regulations


Recently, NanoBio Corporation has announced the progression of a novel intranasal anthrax vaccine into a pre-clinical IND-enabling toxicology study funded by the U.S. National Institute of Health's National Institute of Allergy and Infectious Diseases (NIAID). The vaccine combines NanoBio's novel intranasal nanoemulsion (NE) adjuvant with recombinant protective antigen (rPA) for anthrax from Porton Biopharma Ltd (PBL).


Key Target Audience
Anthrax Vaccines Manufacturers, Distributors, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Live Vaccines
  • Cell free PA Vaccines
By Application
  • Human Use
  • Animal Use
By Disease Type
  • Cutaneous Anthrax
  • Gastrointestinal Anthrax
  • Inhalation Anthrax

By End-users
  • Hospitals
  • Clinics
  • Vaccination Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidences of Anthrax Disease
      • 3.2.2. Rise in the Number of Hospitals and Clinics
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Advancements in the Medical Science
      • 3.4.2. Robust Increase in the Distribution Channels
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anthrax Vaccines, by Type, Application, Disease Type, End-users and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Anthrax Vaccines (Value)
      • 5.2.1. Global Anthrax Vaccines by: Type (Value)
        • 5.2.1.1. Live Vaccines
        • 5.2.1.2. Cell free PA Vaccines
      • 5.2.2. Global Anthrax Vaccines by: Application (Value)
        • 5.2.2.1. Human Use
        • 5.2.2.2. Animal Use
      • 5.2.3. Global Anthrax Vaccines by: Disease Type (Value)
        • 5.2.3.1. Cutaneous Anthrax
        • 5.2.3.2. Gastrointestinal Anthrax
        • 5.2.3.3. Inhalation Anthrax
      • 5.2.4. Global Anthrax Vaccines by: End-users (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinics
        • 5.2.4.3. Vaccination Centers
        • 5.2.4.4. Others
      • 5.2.5. Global Anthrax Vaccines Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Anthrax Vaccines (Volume)
      • 5.3.1. Global Anthrax Vaccines by: Type (Volume)
        • 5.3.1.1. Live Vaccines
        • 5.3.1.2. Cell free PA Vaccines
      • 5.3.2. Global Anthrax Vaccines by: Application (Volume)
        • 5.3.2.1. Human Use
        • 5.3.2.2. Animal Use
      • 5.3.3. Global Anthrax Vaccines by: Disease Type (Volume)
        • 5.3.3.1. Cutaneous Anthrax
        • 5.3.3.2. Gastrointestinal Anthrax
        • 5.3.3.3. Inhalation Anthrax
      • 5.3.4. Global Anthrax Vaccines by: End-users (Volume)
        • 5.3.4.1. Hospitals
        • 5.3.4.2. Clinics
        • 5.3.4.3. Vaccination Centers
        • 5.3.4.4. Others
      • 5.3.5. Global Anthrax Vaccines Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Anthrax Vaccines (Price)
      • 5.4.1. Global Anthrax Vaccines by: Type (Price)
  • 6. Anthrax Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Porton Biopharma Limited (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Colorado Serum Co (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Emergent BioSolutions Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Boehringer Ingelheim Animal Health (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Zoetis Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bayer (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Colorado Serum Co (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. PharmAthene, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Tiankang (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Anthrax Vaccines Sale, by Type, Application, Disease Type, End-users and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Anthrax Vaccines (Value)
      • 7.2.1. Global Anthrax Vaccines by: Type (Value)
        • 7.2.1.1. Live Vaccines
        • 7.2.1.2. Cell free PA Vaccines
      • 7.2.2. Global Anthrax Vaccines by: Application (Value)
        • 7.2.2.1. Human Use
        • 7.2.2.2. Animal Use
      • 7.2.3. Global Anthrax Vaccines by: Disease Type (Value)
        • 7.2.3.1. Cutaneous Anthrax
        • 7.2.3.2. Gastrointestinal Anthrax
        • 7.2.3.3. Inhalation Anthrax
      • 7.2.4. Global Anthrax Vaccines by: End-users (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinics
        • 7.2.4.3. Vaccination Centers
        • 7.2.4.4. Others
      • 7.2.5. Global Anthrax Vaccines Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Anthrax Vaccines (Volume)
      • 7.3.1. Global Anthrax Vaccines by: Type (Volume)
        • 7.3.1.1. Live Vaccines
        • 7.3.1.2. Cell free PA Vaccines
      • 7.3.2. Global Anthrax Vaccines by: Application (Volume)
        • 7.3.2.1. Human Use
        • 7.3.2.2. Animal Use
      • 7.3.3. Global Anthrax Vaccines by: Disease Type (Volume)
        • 7.3.3.1. Cutaneous Anthrax
        • 7.3.3.2. Gastrointestinal Anthrax
        • 7.3.3.3. Inhalation Anthrax
      • 7.3.4. Global Anthrax Vaccines by: End-users (Volume)
        • 7.3.4.1. Hospitals
        • 7.3.4.2. Clinics
        • 7.3.4.3. Vaccination Centers
        • 7.3.4.4. Others
      • 7.3.5. Global Anthrax Vaccines Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Anthrax Vaccines (Price)
      • 7.4.1. Global Anthrax Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anthrax Vaccines: by Type(USD Million)
  • Table 2. Anthrax Vaccines Live Vaccines , by Region USD Million (2014-2019)
  • Table 3. Anthrax Vaccines Cell free PA Vaccines , by Region USD Million (2014-2019)
  • Table 4. Anthrax Vaccines: by Application(USD Million)
  • Table 5. Anthrax Vaccines Human Use , by Region USD Million (2014-2019)
  • Table 6. Anthrax Vaccines Animal Use , by Region USD Million (2014-2019)
  • Table 7. Anthrax Vaccines: by Disease Type(USD Million)
  • Table 8. Anthrax Vaccines Cutaneous Anthrax , by Region USD Million (2014-2019)
  • Table 9. Anthrax Vaccines Gastrointestinal Anthrax , by Region USD Million (2014-2019)
  • Table 10. Anthrax Vaccines Inhalation Anthrax , by Region USD Million (2014-2019)
  • Table 11. Anthrax Vaccines: by End-users(USD Million)
  • Table 12. Anthrax Vaccines Hospitals , by Region USD Million (2014-2019)
  • Table 13. Anthrax Vaccines Clinics , by Region USD Million (2014-2019)
  • Table 14. Anthrax Vaccines Vaccination Centers , by Region USD Million (2014-2019)
  • Table 15. Anthrax Vaccines Others , by Region USD Million (2014-2019)
  • Table 16. South America Anthrax Vaccines, by Country USD Million (2014-2019)
  • Table 17. South America Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 18. South America Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 19. South America Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 20. South America Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 21. Brazil Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 22. Brazil Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 23. Brazil Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 24. Brazil Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 25. Argentina Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 26. Argentina Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 27. Argentina Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 28. Argentina Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 29. Rest of South America Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 30. Rest of South America Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 31. Rest of South America Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 32. Rest of South America Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 33. Asia Pacific Anthrax Vaccines, by Country USD Million (2014-2019)
  • Table 34. Asia Pacific Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 35. Asia Pacific Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 36. Asia Pacific Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 37. Asia Pacific Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 38. China Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 39. China Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 40. China Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 41. China Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 42. Japan Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 43. Japan Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 44. Japan Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 45. Japan Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 46. India Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 47. India Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 48. India Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 49. India Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 50. South Korea Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 51. South Korea Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 52. South Korea Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 53. South Korea Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 54. Taiwan Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 55. Taiwan Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 56. Taiwan Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 57. Taiwan Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 58. Australia Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 59. Australia Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 60. Australia Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 61. Australia Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 62. Rest of Asia-Pacific Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 63. Rest of Asia-Pacific Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 66. Europe Anthrax Vaccines, by Country USD Million (2014-2019)
  • Table 67. Europe Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 68. Europe Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 69. Europe Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 70. Europe Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 71. Germany Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 72. Germany Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 73. Germany Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 74. Germany Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 75. France Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 76. France Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 77. France Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 78. France Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 79. Italy Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 80. Italy Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 81. Italy Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 82. Italy Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 83. United Kingdom Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 84. United Kingdom Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 85. United Kingdom Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 86. United Kingdom Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 87. Netherlands Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 88. Netherlands Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 89. Netherlands Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 90. Netherlands Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 91. Rest of Europe Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 92. Rest of Europe Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 93. Rest of Europe Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 94. Rest of Europe Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 95. MEA Anthrax Vaccines, by Country USD Million (2014-2019)
  • Table 96. MEA Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 97. MEA Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 98. MEA Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 99. MEA Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 100. Middle East Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 101. Middle East Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 102. Middle East Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 103. Middle East Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 104. Africa Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 105. Africa Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 106. Africa Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 107. Africa Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 108. North America Anthrax Vaccines, by Country USD Million (2014-2019)
  • Table 109. North America Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 110. North America Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 111. North America Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 112. North America Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 113. United States Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 114. United States Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 115. United States Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 116. United States Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 117. Canada Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 118. Canada Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 119. Canada Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 120. Canada Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 121. Mexico Anthrax Vaccines, by Type USD Million (2014-2019)
  • Table 122. Mexico Anthrax Vaccines, by Application USD Million (2014-2019)
  • Table 123. Mexico Anthrax Vaccines, by Disease Type USD Million (2014-2019)
  • Table 124. Mexico Anthrax Vaccines, by End-users USD Million (2014-2019)
  • Table 125. Anthrax Vaccines Sales: by Type(K Units)
  • Table 126. Anthrax Vaccines Sales Live Vaccines , by Region K Units (2014-2019)
  • Table 127. Anthrax Vaccines Sales Cell free PA Vaccines , by Region K Units (2014-2019)
  • Table 128. Anthrax Vaccines Sales: by Application(K Units)
  • Table 129. Anthrax Vaccines Sales Human Use , by Region K Units (2014-2019)
  • Table 130. Anthrax Vaccines Sales Animal Use , by Region K Units (2014-2019)
  • Table 131. Anthrax Vaccines Sales: by Disease Type(K Units)
  • Table 132. Anthrax Vaccines Sales Cutaneous Anthrax , by Region K Units (2014-2019)
  • Table 133. Anthrax Vaccines Sales Gastrointestinal Anthrax , by Region K Units (2014-2019)
  • Table 134. Anthrax Vaccines Sales Inhalation Anthrax , by Region K Units (2014-2019)
  • Table 135. Anthrax Vaccines Sales: by End-users(K Units)
  • Table 136. Anthrax Vaccines Sales Hospitals , by Region K Units (2014-2019)
  • Table 137. Anthrax Vaccines Sales Clinics , by Region K Units (2014-2019)
  • Table 138. Anthrax Vaccines Sales Vaccination Centers , by Region K Units (2014-2019)
  • Table 139. Anthrax Vaccines Sales Others , by Region K Units (2014-2019)
  • Table 140. South America Anthrax Vaccines Sales, by Country K Units (2014-2019)
  • Table 141. South America Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 142. South America Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 143. South America Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 144. South America Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 145. Brazil Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 146. Brazil Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 147. Brazil Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 148. Brazil Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 149. Argentina Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 150. Argentina Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 151. Argentina Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 152. Argentina Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 153. Rest of South America Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 154. Rest of South America Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 155. Rest of South America Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 156. Rest of South America Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 157. Asia Pacific Anthrax Vaccines Sales, by Country K Units (2014-2019)
  • Table 158. Asia Pacific Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 159. Asia Pacific Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 160. Asia Pacific Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 161. Asia Pacific Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 162. China Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 163. China Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 164. China Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 165. China Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 166. Japan Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 167. Japan Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 168. Japan Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 169. Japan Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 170. India Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 171. India Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 172. India Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 173. India Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 174. South Korea Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 175. South Korea Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 176. South Korea Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 177. South Korea Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 178. Taiwan Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 179. Taiwan Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 180. Taiwan Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 181. Taiwan Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 182. Australia Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 183. Australia Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 184. Australia Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 185. Australia Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 186. Rest of Asia-Pacific Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 187. Rest of Asia-Pacific Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 188. Rest of Asia-Pacific Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 189. Rest of Asia-Pacific Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 190. Europe Anthrax Vaccines Sales, by Country K Units (2014-2019)
  • Table 191. Europe Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 192. Europe Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 193. Europe Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 194. Europe Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 195. Germany Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 196. Germany Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 197. Germany Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 198. Germany Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 199. France Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 200. France Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 201. France Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 202. France Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 203. Italy Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 204. Italy Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 205. Italy Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 206. Italy Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 207. United Kingdom Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 208. United Kingdom Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 209. United Kingdom Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 210. United Kingdom Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 211. Netherlands Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 212. Netherlands Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 213. Netherlands Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 214. Netherlands Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 215. Rest of Europe Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 216. Rest of Europe Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 217. Rest of Europe Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 218. Rest of Europe Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 219. MEA Anthrax Vaccines Sales, by Country K Units (2014-2019)
  • Table 220. MEA Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 221. MEA Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 222. MEA Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 223. MEA Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 224. Middle East Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 225. Middle East Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 226. Middle East Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 227. Middle East Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 228. Africa Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 229. Africa Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 230. Africa Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 231. Africa Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 232. North America Anthrax Vaccines Sales, by Country K Units (2014-2019)
  • Table 233. North America Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 234. North America Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 235. North America Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 236. North America Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 237. United States Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 238. United States Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 239. United States Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 240. United States Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 241. Canada Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 242. Canada Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 243. Canada Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 244. Canada Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 245. Mexico Anthrax Vaccines Sales, by Type K Units (2014-2019)
  • Table 246. Mexico Anthrax Vaccines Sales, by Application K Units (2014-2019)
  • Table 247. Mexico Anthrax Vaccines Sales, by Disease Type K Units (2014-2019)
  • Table 248. Mexico Anthrax Vaccines Sales, by End-users K Units (2014-2019)
  • Table 249. Anthrax Vaccines: by Type(USD/Units)
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Anthrax Vaccines: by Type(USD Million)
  • Table 261. Anthrax Vaccines Live Vaccines , by Region USD Million (2020-2025)
  • Table 262. Anthrax Vaccines Cell free PA Vaccines , by Region USD Million (2020-2025)
  • Table 263. Anthrax Vaccines: by Application(USD Million)
  • Table 264. Anthrax Vaccines Human Use , by Region USD Million (2020-2025)
  • Table 265. Anthrax Vaccines Animal Use , by Region USD Million (2020-2025)
  • Table 266. Anthrax Vaccines: by Disease Type(USD Million)
  • Table 267. Anthrax Vaccines Cutaneous Anthrax , by Region USD Million (2020-2025)
  • Table 268. Anthrax Vaccines Gastrointestinal Anthrax , by Region USD Million (2020-2025)
  • Table 269. Anthrax Vaccines Inhalation Anthrax , by Region USD Million (2020-2025)
  • Table 270. Anthrax Vaccines: by End-users(USD Million)
  • Table 271. Anthrax Vaccines Hospitals , by Region USD Million (2020-2025)
  • Table 272. Anthrax Vaccines Clinics , by Region USD Million (2020-2025)
  • Table 273. Anthrax Vaccines Vaccination Centers , by Region USD Million (2020-2025)
  • Table 274. Anthrax Vaccines Others , by Region USD Million (2020-2025)
  • Table 275. South America Anthrax Vaccines, by Country USD Million (2020-2025)
  • Table 276. South America Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 277. South America Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 278. South America Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 279. South America Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 280. Brazil Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 281. Brazil Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 282. Brazil Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 283. Brazil Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 284. Argentina Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 285. Argentina Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 286. Argentina Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 287. Argentina Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 288. Rest of South America Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 289. Rest of South America Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 290. Rest of South America Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 291. Rest of South America Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 292. Asia Pacific Anthrax Vaccines, by Country USD Million (2020-2025)
  • Table 293. Asia Pacific Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 294. Asia Pacific Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 295. Asia Pacific Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 296. Asia Pacific Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 297. China Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 298. China Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 299. China Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 300. China Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 301. Japan Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 302. Japan Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 303. Japan Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 304. Japan Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 305. India Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 306. India Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 307. India Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 308. India Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 309. South Korea Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 310. South Korea Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 311. South Korea Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 312. South Korea Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 313. Taiwan Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 314. Taiwan Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 315. Taiwan Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 316. Taiwan Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 317. Australia Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 318. Australia Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 319. Australia Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 320. Australia Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 321. Rest of Asia-Pacific Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 322. Rest of Asia-Pacific Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 323. Rest of Asia-Pacific Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 324. Rest of Asia-Pacific Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 325. Europe Anthrax Vaccines, by Country USD Million (2020-2025)
  • Table 326. Europe Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 327. Europe Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 328. Europe Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 329. Europe Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 330. Germany Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 331. Germany Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 332. Germany Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 333. Germany Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 334. France Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 335. France Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 336. France Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 337. France Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 338. Italy Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 339. Italy Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 340. Italy Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 341. Italy Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 342. United Kingdom Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 343. United Kingdom Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 344. United Kingdom Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 345. United Kingdom Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 346. Netherlands Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 347. Netherlands Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 348. Netherlands Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 349. Netherlands Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 350. Rest of Europe Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 351. Rest of Europe Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 352. Rest of Europe Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 353. Rest of Europe Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 354. MEA Anthrax Vaccines, by Country USD Million (2020-2025)
  • Table 355. MEA Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 356. MEA Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 357. MEA Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 358. MEA Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 359. Middle East Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 360. Middle East Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 361. Middle East Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 362. Middle East Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 363. Africa Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 364. Africa Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 365. Africa Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 366. Africa Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 367. North America Anthrax Vaccines, by Country USD Million (2020-2025)
  • Table 368. North America Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 369. North America Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 370. North America Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 371. North America Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 372. United States Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 373. United States Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 374. United States Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 375. United States Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 376. Canada Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 377. Canada Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 378. Canada Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 379. Canada Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 380. Mexico Anthrax Vaccines, by Type USD Million (2020-2025)
  • Table 381. Mexico Anthrax Vaccines, by Application USD Million (2020-2025)
  • Table 382. Mexico Anthrax Vaccines, by Disease Type USD Million (2020-2025)
  • Table 383. Mexico Anthrax Vaccines, by End-users USD Million (2020-2025)
  • Table 384. Anthrax Vaccines Sales: by Type(K Units)
  • Table 385. Anthrax Vaccines Sales Live Vaccines , by Region K Units (2020-2025)
  • Table 386. Anthrax Vaccines Sales Cell free PA Vaccines , by Region K Units (2020-2025)
  • Table 387. Anthrax Vaccines Sales: by Application(K Units)
  • Table 388. Anthrax Vaccines Sales Human Use , by Region K Units (2020-2025)
  • Table 389. Anthrax Vaccines Sales Animal Use , by Region K Units (2020-2025)
  • Table 390. Anthrax Vaccines Sales: by Disease Type(K Units)
  • Table 391. Anthrax Vaccines Sales Cutaneous Anthrax , by Region K Units (2020-2025)
  • Table 392. Anthrax Vaccines Sales Gastrointestinal Anthrax , by Region K Units (2020-2025)
  • Table 393. Anthrax Vaccines Sales Inhalation Anthrax , by Region K Units (2020-2025)
  • Table 394. Anthrax Vaccines Sales: by End-users(K Units)
  • Table 395. Anthrax Vaccines Sales Hospitals , by Region K Units (2020-2025)
  • Table 396. Anthrax Vaccines Sales Clinics , by Region K Units (2020-2025)
  • Table 397. Anthrax Vaccines Sales Vaccination Centers , by Region K Units (2020-2025)
  • Table 398. Anthrax Vaccines Sales Others , by Region K Units (2020-2025)
  • Table 399. South America Anthrax Vaccines Sales, by Country K Units (2020-2025)
  • Table 400. South America Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 401. South America Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 402. South America Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 403. South America Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 404. Brazil Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 405. Brazil Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 406. Brazil Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 407. Brazil Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 408. Argentina Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 409. Argentina Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 410. Argentina Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 411. Argentina Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 412. Rest of South America Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 413. Rest of South America Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 414. Rest of South America Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 415. Rest of South America Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 416. Asia Pacific Anthrax Vaccines Sales, by Country K Units (2020-2025)
  • Table 417. Asia Pacific Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 418. Asia Pacific Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 419. Asia Pacific Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 420. Asia Pacific Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 421. China Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 422. China Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 423. China Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 424. China Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 425. Japan Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 426. Japan Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 427. Japan Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 428. Japan Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 429. India Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 430. India Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 431. India Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 432. India Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 433. South Korea Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 434. South Korea Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 435. South Korea Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 436. South Korea Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 437. Taiwan Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 438. Taiwan Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 439. Taiwan Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 440. Taiwan Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 441. Australia Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 442. Australia Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 443. Australia Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 444. Australia Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 445. Rest of Asia-Pacific Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 446. Rest of Asia-Pacific Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 447. Rest of Asia-Pacific Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 448. Rest of Asia-Pacific Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 449. Europe Anthrax Vaccines Sales, by Country K Units (2020-2025)
  • Table 450. Europe Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 451. Europe Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 452. Europe Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 453. Europe Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 454. Germany Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 455. Germany Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 456. Germany Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 457. Germany Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 458. France Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 459. France Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 460. France Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 461. France Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 462. Italy Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 463. Italy Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 464. Italy Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 465. Italy Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 466. United Kingdom Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 467. United Kingdom Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 468. United Kingdom Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 469. United Kingdom Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 470. Netherlands Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 471. Netherlands Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 472. Netherlands Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 473. Netherlands Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 474. Rest of Europe Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 475. Rest of Europe Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 476. Rest of Europe Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 477. Rest of Europe Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 478. MEA Anthrax Vaccines Sales, by Country K Units (2020-2025)
  • Table 479. MEA Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 480. MEA Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 481. MEA Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 482. MEA Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 483. Middle East Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 484. Middle East Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 485. Middle East Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 486. Middle East Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 487. Africa Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 488. Africa Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 489. Africa Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 490. Africa Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 491. North America Anthrax Vaccines Sales, by Country K Units (2020-2025)
  • Table 492. North America Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 493. North America Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 494. North America Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 495. North America Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 496. United States Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 497. United States Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 498. United States Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 499. United States Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 500. Canada Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 501. Canada Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 502. Canada Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 503. Canada Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 504. Mexico Anthrax Vaccines Sales, by Type K Units (2020-2025)
  • Table 505. Mexico Anthrax Vaccines Sales, by Application K Units (2020-2025)
  • Table 506. Mexico Anthrax Vaccines Sales, by Disease Type K Units (2020-2025)
  • Table 507. Mexico Anthrax Vaccines Sales, by End-users K Units (2020-2025)
  • Table 508. Anthrax Vaccines: by Type(USD/Units)
  • Table 509. Research Programs/Design for This Report
  • Table 510. Key Data Information from Secondary Sources
  • Table 511. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anthrax Vaccines: by Type USD Million (2014-2019)
  • Figure 5. Global Anthrax Vaccines: by Application USD Million (2014-2019)
  • Figure 6. Global Anthrax Vaccines: by Disease Type USD Million (2014-2019)
  • Figure 7. Global Anthrax Vaccines: by End-users USD Million (2014-2019)
  • Figure 8. South America Anthrax Vaccines Share (%), by Country
  • Figure 9. Asia Pacific Anthrax Vaccines Share (%), by Country
  • Figure 10. Europe Anthrax Vaccines Share (%), by Country
  • Figure 11. MEA Anthrax Vaccines Share (%), by Country
  • Figure 12. North America Anthrax Vaccines Share (%), by Country
  • Figure 13. Global Anthrax Vaccines: by Type K Units (2014-2019)
  • Figure 14. Global Anthrax Vaccines: by Application K Units (2014-2019)
  • Figure 15. Global Anthrax Vaccines: by Disease Type K Units (2014-2019)
  • Figure 16. Global Anthrax Vaccines: by End-users K Units (2014-2019)
  • Figure 17. South America Anthrax Vaccines Share (%), by Country
  • Figure 18. Asia Pacific Anthrax Vaccines Share (%), by Country
  • Figure 19. Europe Anthrax Vaccines Share (%), by Country
  • Figure 20. MEA Anthrax Vaccines Share (%), by Country
  • Figure 21. North America Anthrax Vaccines Share (%), by Country
  • Figure 22. Global Anthrax Vaccines: by Type USD/Units (2014-2019)
  • Figure 23. Global Anthrax Vaccines share by Players 2019 (%)
  • Figure 24. Global Anthrax Vaccines share by Players (Top 3) 2019(%)
  • Figure 25. Global Anthrax Vaccines share by Players (Top 5) 2019(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Porton Biopharma Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. Porton Biopharma Limited (United Kingdom) Revenue: by Geography 2019
  • Figure 29. Colorado Serum Co (United States) Revenue, Net Income and Gross profit
  • Figure 30. Colorado Serum Co (United States) Revenue: by Geography 2019
  • Figure 31. Emergent BioSolutions Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Emergent BioSolutions Inc. (United States) Revenue: by Geography 2019
  • Figure 33. Boehringer Ingelheim Animal Health (France) Revenue, Net Income and Gross profit
  • Figure 34. Boehringer Ingelheim Animal Health (France) Revenue: by Geography 2019
  • Figure 35. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Merck & Co. (United States) Revenue: by Geography 2019
  • Figure 37. Zoetis Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Zoetis Inc. (United States) Revenue: by Geography 2019
  • Figure 39. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 40. Bayer (Germany) Revenue: by Geography 2019
  • Figure 41. Colorado Serum Co (United States) Revenue, Net Income and Gross profit
  • Figure 42. Colorado Serum Co (United States) Revenue: by Geography 2019
  • Figure 43. PharmAthene, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. PharmAthene, Inc. (United States) Revenue: by Geography 2019
  • Figure 45. Tiankang (China) Revenue, Net Income and Gross profit
  • Figure 46. Tiankang (China) Revenue: by Geography 2019
  • Figure 47. Global Anthrax Vaccines: by Type USD Million (2020-2025)
  • Figure 48. Global Anthrax Vaccines: by Application USD Million (2020-2025)
  • Figure 49. Global Anthrax Vaccines: by Disease Type USD Million (2020-2025)
  • Figure 50. Global Anthrax Vaccines: by End-users USD Million (2020-2025)
  • Figure 51. South America Anthrax Vaccines Share (%), by Country
  • Figure 52. Asia Pacific Anthrax Vaccines Share (%), by Country
  • Figure 53. Europe Anthrax Vaccines Share (%), by Country
  • Figure 54. MEA Anthrax Vaccines Share (%), by Country
  • Figure 55. North America Anthrax Vaccines Share (%), by Country
  • Figure 56. Global Anthrax Vaccines: by Type K Units (2020-2025)
  • Figure 57. Global Anthrax Vaccines: by Application K Units (2020-2025)
  • Figure 58. Global Anthrax Vaccines: by Disease Type K Units (2020-2025)
  • Figure 59. Global Anthrax Vaccines: by End-users K Units (2020-2025)
  • Figure 60. South America Anthrax Vaccines Share (%), by Country
  • Figure 61. Asia Pacific Anthrax Vaccines Share (%), by Country
  • Figure 62. Europe Anthrax Vaccines Share (%), by Country
  • Figure 63. MEA Anthrax Vaccines Share (%), by Country
  • Figure 64. North America Anthrax Vaccines Share (%), by Country
  • Figure 65. Global Anthrax Vaccines: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • Porton Biopharma Limited (United Kingdom)
  • Colorado Serum Co (United States)
  • Emergent BioSolutions Inc. (United States)
  • Boehringer Ingelheim Animal Health (France)
  • Merck & Co. (United States)
  • Zoetis Inc. (United States)
  • Bayer (Germany)
  • Colorado Serum Co (United States)
  • PharmAthene, Inc. (United States)
  • Tiankang (China)
Additional players considered in the study are as follows:
Biogenesis Bago SA (Argentina) , Instituto Rosenbusch SA (Argentina)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation